

# AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2011

## AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas Vasanji Road,  
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 31.03.2012 Unaudited	Quarter ended 31.03.2012 (Audited)	Quarter ended 31.03.2011 Unaudited	Year ended 31.12.2012 (Audited)
<b>1 (a) Net Sales</b>	3,225	3,379	2,763	12,297
<b>(b) Other Operating Income</b>	232	207	207	856
<b>Total</b>	3,457	3,586	2,970	13,153
<b>2 Expenditure</b>				
<b>(a) (Increase)/Decrease in stock in trade and work in progress</b>	(215)	(70)	(66)	(76)
<b>(b) Consumption of raw materials</b>	1,322	1,293	1,192	4,916
<b>(c) Purchase of traded goods</b>	478	494	235	1,353
<b>(d) Employee cost</b>	490	503	405	1,764
<b>(e) Depreciation</b>	183	142	54	311
<b>(f) Other expenditure</b>	658	764	562	2,579

Particulars	Quarter ended 31.03.2012 Unaudited	Quarter ended 31.03.2012 (Audited)	Quarter ended 31.03.2011 Unaudited	Year ended 31.12.2012 (Audited)
<b>(g) Total</b>	2,916	3,126	2,382	10,847
<b>3 Profit from Operations before Other Income and Interest (1-2)</b>	541	460	588	2,306
<b>4 Other Income</b>	57	80	172	538
<b>5 Profit before Interest (3+4)</b>	598	540	760	2,844
<b>6 Interest</b>	4	4	2	4
<b>7 Profit before tax and Exceptional items (5-6)</b>	594	536	768	2,840
<b>8 Tax Expense</b>	193	175	252	928
<b>9 Net Profit for the period before Exceptional items (7-8)</b>	401	361	506	1,921
<b>10 Exceptional item (net of tax)</b>	-	-	-	-
<b>11 Net Profit for the period after Exceptional items (9+10)</b>	401	361	506	1,912
<b>12 Paid-up equity share capital (Face Value of Rs. 10 per Share)</b>	230	230	230	230
<b>13 Reserves excluding</b>				10,781

Particulars	Quarter ended 31.03.2012 Unaudited	Quarter ended 31.03.2012 (Audited)	Quarter ended 31.03.2011 Unaudited	Year ended 31.12.2012 (Audited)
<b>Revaluation Reserves as per balance sheet of previous accounting year</b>				
<b>14 Earnings Per Share (EPS) before Exceptional items (Rs.)</b> (Basic and diluted EPS for the period and for the previous year)	17.43	15.70	22.00	83.13
<b>15 Earnings Per Share (EPS) after Exceptional items (Rs.)</b> (Basic and diluted EPS for the period and for the previous year)	17.43	15.70	22.00	83.13
<b>16 Public Shareholding</b>				
- Number of Shares	9,121,035	9,121,035	9,121,035	9,121,035
- Percentage of Shareholding	39.60	39.60	39.60	39.60
<b>17 Promoters and Promoter group Shareholding</b>				
<b>a) Pledged/Encumbered</b>				
- Number of shares	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total shareholding of promoter and promoter)	NIL	NIL	NIL	

Particulars	Quarter ended 31.03.2012 Unaudited	Quarter ended 31.03.2012 (Audited)	Quarter ended 31.03.2011 Unaudited	Year ended 31.12.2012 (Audited)
group)				
- Percentage of shares (as a % of total share capital of the company)	NIL	NIL	NIL	
<b>b) Non-encumbered</b>				
- Number of shares	13,909,587	13,909,587	13,909,587	13,909,587
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of total share capital of the company)	60.40%	60.40%	60.40%	60.40%

Particulars	3 Months ended March 31,2012
<b>B. INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	NIL
Received during the quarter	27
Disposed of during the quarter	NIL
Remaining unresolved at the end of the quarter	27

## Notes:

1. The above Results were approved by the Board of Directors of the Company at its Meeting held on May 3, 2012.

2. 2. In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended March 31, 2012.
3. 3. The Board of Directors had, at its Meeting held on February 23 , 2012 , recommended a Final dividend of Rs. 29 per Equity share of Rs.10 for the year ended December 31, 2011.The said dividend, if declared at the Annual General Meeting to be held on May 3, 2012 , will be paid on May 10 , 2012.
4. 4. The profit for the quarter ended March 31, 2012 has been impacted due to the amortization costs relating to the brands and technical know-how acquired in 2011 from Universal Medicare Private Limited and lower interest income as a result of the above investment.
5. 5. The Company has a single business segment namely 'Pharmaceutical Business'.
6. 6. The figures for the quarter ended December 31,2011 are the balancing figures between audited figures in respect of the full financial year up to December 31, 2011 and the unaudited published year-to-date figures up to September 30, 2011 being the date of the end of the third quarter of the said financial year.
7. 7. The figures for the previous periods have been re-grouped, wherever necessary.

**AVENTIS PHARMA LIMITED**  
**DR. SHAILESH AYYANGAR**  
**MANAGING DIRECTOR**